微生物与生化药学方向

赵午莉

来源:    

作者:    

时间:2021-12-01    

浏览次数:


赵午莉 肿瘤室 副研究员 硕士生导师

教育背景及工作经历:本科和研究生毕业于天津医科大学,博士毕业于中国医学科学院协和医学院医药生物技术研究所。毕业后就职于医科院医药生物技术研究所。

主要研究方向:靶向抗肿瘤药物研发

专业研究领域:①筛选多种靶向抗肿瘤药物,研究其抗肿瘤机制;②开展了癌基因活性研究以及其靶向治疗,研究了靶基因MR-1在慢性粒细胞急性变,肺癌,大肠癌中的作用以及其靶向活性,对其对促肿瘤增殖的机制进行了深入研究。③对抗癌药物米铂脂质体抗肿瘤活性及机制深入研究,确定脂质体类药物如何入胞,入胞代谢途径以及如何产生抗肿瘤活性进行了深入研究。


代表性论文:

1 Wang JX, Chen MH, Wang MY, Zhao WX, Zhao WL, Si SY, Shao RG. The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells. Acta Pharmacol Sin B 2021 (In Press) (IF: 11.6).

2 Zhao WL, Liu H, Wang J, Wang M, Shao R. Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127). J Exp Clin Cancer Res 2018; 37: 98. (IF: 7.068)

3 ZhaoWX, Wang MY, Zhao WX, Zhao WL, Shao RG et al., Transcriptional co-activators YAP/TAZ: potential therapeutic targets for metastatic breast cancer. Biomedicine & Pharmacotherapy, 2021. 133: p. 110956. ( IF: 6.521)

4 Zhao WL, Xing Y, Ye C, Qiu YH, Li Y, Liu XJ, et al. The novel quinolizidine derivate IMB-HDC inhibits STAT5a phosphorylation at 694 and 780 and promotes DNA breakage and cell apoptosis via blocking STAT5a nuclear translocation. Acta Pharmacol Sin 2020; 41: 686-97. (IF: 6.530)

5 Qiu, YH. Zhao WL, Shao RG, et al., Mitochondria autophagy: a potential target for cancer therapy. Journal of Drug Targeting, 2021. 29(6): p. 576-591.Wang MY, Qiu YH, Cai ML, Zhang CH, Wang XW, Liu H, Zhao WL, et al. Role and molecular mechanism of stem cells in colorectal cancer initiation. J Drug Target 2020; 28: 1-10. (IF: 5.124)

6 Wang, X, Zhao WL, Shao RG., et al., Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy. International Journal of Nanomedicine, 2020. 15: p. 9447. (6.404).

7 Cai ML, Wang MY, Zhang CH, Wang JX, Liu H, He HW, Zhao WL, et al. Role of co- and post-translational modifications of SFKs in their kinase activation. J Drug Target 2020; 28: 23-32. (IF: 5.124).

8 Zhang CH, Wang JX, Cai ML, Shao R, Liu H, Zhao WL. The roles and mechanisms of G3BP1 in tumour promotion. J Drug Target 2019; 27: 300-5. (IF: 5.124)

9 Wang J, Zhao WL, Liu H, He H, Shao R. Myofibrillogenesis regulator 1 (MR-1): a potential therapeutic target for cancer and PNKD. J Drug Target 2018; 26: 643-8. (IF: 5.08)

10 Zhao WL, He H, Ren K, Li B, Zhang H, Lin Y, et al. MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation. Blood Cancer J 2013; 3: e107. (IF: 8.023)

专利:

1.多硫代二酮哌嗪类化合物Secoemestrin C的准备方法及其用途, CN105748448A_D

2.手性肌醇在制备抗肝纤维化药物中的应用,CN105748448A

3. . 环化的小檗碱衍生物及其制备方法和用途,CN201210101607.x

专著:大百科词典

荣誉奖励:1.获得第十一届中国药学会科学技术奖二等奖,基于三环苦参骨架生物碱类衍生物的生物活性与化学基础(2016);2.获得“药学学报第七届优秀研究论文奖” (2013).

学术任职 Journl of Clinical Translation Heptology (IF: 4.1)杂志青年编委,Animal Models and Experimental Medicine (IF: 2.3)杂志青年编委。老年病委员会委员,中国健康管理协会下筹备食用植物营养与健康委员。

联系电话:010-83166673

电子邮箱:wenlyzh@imb.pumc.edu.cn